CTXR · Citius Pharmaceuticals, Inc.
$0.50
+0.01 (+2.19%)
At close · Oct 9
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company estimates that its and Citius Oncology's collective available cash resources will be sufficient to fund our operations through November 2026. We will need to raise additional capital in the future to support our operations beyond November 2026, which raises substantial doubt about the Company's ability to continue as a going concern within one year after the date that the accompanying consolidated financial statements are issued.”View the 10-Q filed Aug 14, 2026
Market Cap
$13.73M
Shares
27.45M
Volume · Oct 9
144.28K
Avg daily vol (3M)
522.28K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.50
Open$0.49
Day$0.48–0.51
52W close$0.48–1.82
Avg vol 30d199K
Short int5.6M · 20.4% float · 30.5d
Short vol31%
Last earningsAug 13, 2024
DataJan 2020–Oct 2026
Filing10-Q · Aug 14
Up next
filed Aug 14, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-62.0%
Trailing year
Short interest
20.4%
Latest settlement · 30.5 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 14.8 · calm
Equity put/call 0.56
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−27%
below
Price vs 50-day avg
−16%
below
RSI (14)
40
neutral
MACD trend
Negative
52-week position
1%
near low
Momentum
relative strength
1-month return
−14%
trailing
6-month return
−43%
trailing
YTD return
−36%
this year
Relative strength
−53%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+8% holders QoQ · +11 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
20.36% of float · ▲ +0.5% MoM · 30.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
42 holders — mid 3-yr range
Squeeze score
70
high risk · 0–100
Fundamentals
EPS growth
+43%
Y/Y
Free cash flow
$-26.6M
Quant / Vol
risk profile
Volatility
112%
annualized · 1-yr
Max drawdown
−74%
past year
ATR
7.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−27%
Bearish
Price vs 50-day avg
−16%
Bearish
RSI (14)
40
Neutral
MACD trend
Negative
Bearish
52-week position
1%
Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+8% holders QoQ · +11 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
20.36% of float · ▲ +0.5% MoM · 30.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
42 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $0
Now $0 · 1%
Range high $2
vs 200-day avg -27%
vs 50-day avg -16%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CTXR
this stock
Citius Pharmaceuticals, Inc.
|
$13.73M | -35.7% | +0.0% | — | 20.4% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$127.55B | +12.5% | +46.2% | 29.3 | 1.8% |
|
MRNA
Moderna, Inc.
|
$89.83B | +663.0% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$76.86B | -3.3% | +20.8% | 18.5 | 2.1% |
|
CSLLY
Csl Ltd
|
$61.58B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CTXR | -6.1% | -14.0% | -42.9% | -6.0% | -35.7% |
| SPY | +1.2% | +1.9% | +9.9% | +2.1% | +14.2% |
| vs SPY | -7.2% | -15.9% | -52.7% | -8.0% | -49.9% |